Thyroid Disease CARE Act of 2025

1) What happened: Representative Stevens (D-MI) introduced HR6897, the Thyroid Disease CARE Act of 2025, on December 18, 2025. The bill was referred to the House Committee on Energy and Commerce, where it remains with no further action. With only one cosponsor (Rep. Underwood, D-IL), the bill has narrow bipartisan support, and the current House majority (Republicans) has not advanced it. 2) The money trail: Section 2(c) authorizes $30 million per fiscal year for 2026 through 2030 — a total of $150 million. This is an AUTHORIZATION, not an appropriation. The actual spending requires a separate appropriations bill passed by both chambers. Given the current fiscal environment and the bill's early stage, no funds are currently allocated. 3) Structural winners and losers: Companies in thyroid diagnostics and research tools ($DGX, $LH, $TMO, , ) would be the most directly exposed if the bill progresses and appropriations are made. However, $150 million over five years is modest — roughly equivalent to 0.1-0.3% of annual revenue for these companies. No company receives a direct earmark. 4) Market data context: As of April 30, 2026, thyroid diagnostic companies show weakness. trades at $90.50, near its 52-week low of $90.29, with a 30-day decline of 11.85%. $LH is down 1.53% over 30 days to $262.73. $DGX is essentially flat over 30 days (-0.41%) at $195.17. Research tool provider $TMO has fallen 3.42% in 30 days to $474.70. These moves are unrelated to a bill that has been dormant for over four months. 5) Timeline: The bill requires committee markup in Energy and Commerce, House floor passage, Senate companion introduction and passage, then presidential signature. With a single cosponsor and a Democratic lead sponsor in a Republican-controlled House, the probability of passage in the 119th Congress is low. No hearings or markups have been scheduled as of April 30, 2026.